Invasive Aspergillosis
📧 Sign up to get email alerts when something new happens for Invasive Aspergillosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-03-09FDA Approved: VORICONAZOLE — Original Application (Xellia Pharmaceuticals USA LLC)
FDA approved voriconazole via an Original Application submitted by Xellia Pharmaceuticals USA LLC (NDA208562).
-
CLINICAL_TRIALS trial_result · 2017-02-02Clinical Trial Update: Study of Potential for Interaction of Fluconazole With F901318 [Phase 1]
A Phase 1 study completed to assess potential pharmacokinetic interaction between fluconazole and F901318 in invasive aspergillosis.
-
CLINICAL_TRIALS trial_result · 2016-11-28Clinical Trial Update: Evaluation of Immediate Release Tablet [Phase 1]
Phase 1 clinical trial of an immediate-release tablet for invasive aspergillosis has completed.
-
CLINICAL_TRIALS trial_result · 2016-09-19Clinical Trial Update: Single Ascending Oral Dose Study of F901318 [Phase 1]
A Phase 1 single ascending oral dose study of F901318 in invasive aspergillosis has been completed.
-
CLINICAL_TRIALS trial_result · 2016-09-19Clinical Trial Update: F901318 Multiple Ascending Dose Study [Phase 1]
A Phase 1 multiple ascending dose study of F901318 for invasive aspergillosis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-09-14Clinical Trial Update: Invasives Aspergillosis in Acute Myeloid Leukemia
A clinical trial evaluating invasive aspergillosis in patients with acute myeloid leukemia has completed.
-
CLINICAL_TRIALS research · 2016-08-03Clinical Trial Update: Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia. [NA]
A completed clinical trial evaluated whether beta-1,3-D-glucan assays can help screen for the onset of invasive aspergillosis in neutropenic…
-
CLINICAL_TRIALS trial_result · 2016-06-09Clinical Trial Update: Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe [Phase 1]
Phase 1 trial completed to evaluate the potential of F901318 to inhibit CYP3A4 using oral midazolam as a probe. The study assesses drug–drug…
-
FDA approval · 2016-05-31FDA Approved: VORICONAZOLE — Original Application (Lupin Pharmaceuticals,Inc.)
FDA approval of Lupin's original application for a generic voriconazole product used to treat invasive fungal infections, including invasive…
-
FDA approval · 2016-05-24FDA Approved: VORICONAZOLE — Original Application (Zydus Lifesciences Limited)
FDA approved the original application for Voriconazole from Zydus Lifesciences Limited, granting approval for a generic Voriconazole product…
-
FDA approval · 2016-05-24FDA Approved: VORICONAZOLE — Original Application (Ajanta Pharma USA Inc.)
FDA approved a generic version of voriconazole from Ajanta Pharma USA Inc. under an Original Application, for treatment of invasive aspergil…
-
FDA approval · 2016-05-24FDA Approved: VORICONAZOLE — Original Application (Lupin Pharmaceuticals,Inc.)
FDA approved Lupin Pharmaceuticals' generic voriconazole through an Original Application (ANDA); the product is indicated for treating invas…
-
CLINICAL_TRIALS research · 2016-05-16Clinical Trial Update: An Evaluation of Sequential Computed Tomography of the Chest in Management of Invasive Pulmonal Aspergillosis in Neutropenic Patients With Haematological Malignancies
Clinical trial update evaluating sequential chest CT scans for managing invasive aspergillosis in neutropenic patients with hematologic mali…
-
FDA approval · 2016-04-13FDA Approved: VORICONAZOLE — Original Application (Amneal Pharmaceuticals LLC)
FDA approves Amneal's original-application generic Voriconazole (voriconazole) for its approved antifungal indications.
-
FDA approval · 2016-01-22FDA Approved: VORICONAZOLE — Original Application (Aurobindo Pharma Limited)
FDA approved Voriconazole from Aurobindo Pharma Limited via an Original Application (ANDA), introducing a generic version of voriconazole. T…
-
FDA approval · 2016-01-12FDA Approved: VORICONAZOLE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Voriconazole submitted by Mylan Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2016-01-11Clinical Trial Update: Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi [Phase 3]
Phase 3 trial update evaluating isavuconazole for renally impaired patients with invasive aspergillosis and rare fungal infections; results …
-
FDA approval · 2016-01-05FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Cresemba (isavuconazonium sulfate) from Astellas Pharma US, expanding its approved indications. …
-
FDA approval · 2015-10-23FDA Approved: VORICONAZOLE — Supplemental Application (Sandoz Inc)
FDA approves a supplemental application for voriconazole (VORICONAZOLE) from Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2015-10-23Clinical Trial Update: Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia [Phase 2]
Phase 2 trial evaluating nebulized amphotericin B lipid complex for invasive aspergillosis in pediatric patients with acute leukemia has com…
-
CLINICAL_TRIALS trial_result · 2015-09-07Clinical Trial Update: F901318 Single Ascending Dose Study in Healthy Male Volunteers [Phase 1]
Phase 1 single ascending dose study of F901318 in healthy male volunteers; results were posted in 2015.
-
FDA approval · 2015-09-02FDA Approved: VORICONAZOLE — Original Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark's original application for a generic Voriconazole (ANDA 203503), enabling the generic antifungal to be marketed in…
-
CLINICAL_TRIALS withdrawal · 2015-09-02Clinical Trial Update: A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis [Phase 4]
This Phase 4 trial evaluating voriconazole plus micafungin versus voriconazole alone for invasive aspergillosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-07-09Clinical Trial Update: COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis [Phase 4]
A Phase 4 study evaluating the combination of AmBisome (liposomal amphotericin B) with caspofungin for invasive aspergillosis has completed.
-
FDA approval · 2015-04-03FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for CRESEMBA (isavuconazonium sulfate) from Astellas Pharma US, Inc., to support changes to the prod…